Novo Nordisk AS is preparing to file an sNDA with FDA and European regulators for the glucagon-like peptide-1 (GLP-1) agonist Victoza (liraglutide) this fall to incorporate new data highlighting the drug’s cardiovascular benefits.
The Danish diabetes specialist presented positive data from the LEADER cardiovascular outcomes trial, testing Victoza versus placebo in patients with diabetes at high-risk of cardiovascular events, at the American Diabetes...